$VYCO razor-thin float: The Company Should Enter Hyper-growth During the Next Two to Three Years.
Vycor's ViewSite is already making good inroads into the relatively small neurosurgery
market, both in the U.S. and overseas, and we expect sales to grow robustly beginning in early
2013. However, we are most excited about the long-term potential of the NovaVision
subsidiary, as its products have no real competition and address a global market that could be
up to $20B in size. Although NovaVision's products could require several years to achieve
market penetration of even 5%, this would still equate to a huge win for a company of this size.
Both NovaVision and ViewSite have strong patent protection and backing from the scientific
community, and both are FDA 510(k) cleared for sale in the United States.
-Harbinger Research
Obligatory/cliche "Girl Standing Next To Hot Car" signature
![](//investorshub.advfn.com/uimage/uploads/2012/4/19/xtuzhThe-Girl-With-the-Dragon-Tattoo-car-hd-wallpaper_(1).jpg)